A b s t r a c t
Colorectal cancer with microsatellite instability (MSI) may occur sporadically or be inherited in cases of hereditary nonpolyposis colorectal cancer (HNPCC) syndrome. However, there is no consensus as to which patients must be tested and how to test MSI. In this study, MSI was tested by immunohistochemical analysis and by polymerase chain reaction in 148 cases of colorectal cancer, and methylation of the hMLH1 promoter was examined. MSI status was correlated with tumor phenotype. We found that localization, tumor infiltrating lymphocytes, and mucinous differentiation were predictive of high-frequency MSI (MSI-H) colorectal cancer and might be used to select cases for MSI analysis. Immunohistochemical analysis detected most MSI-H colorectal cancer and might constitute the first step in MSI detection. Absence of hMLH1 promoter methylation in MSI-H colorectal cancer could be predictive of hereditary colorectal cancer, and, hence, methylation analysis might constitute the second step in the identification of patients with HNPCC.
Colon cancer results from the progressive accumulation of genetic and epigenetic alterations that lead to the transformation of normal colonic epithelium to adenocarcinoma of the colon. However, adenocarcinomas of the colon and rectum arise through at least 2 molecular genetic pathways. The majority of colorectal carcinomas (CRCs; 85%) arise through chromosomal instability, which involves the wnt signaling pathway, whereas 10% to 15% of tumors arise through microsatellite instability (MSI). [1] [2] [3] [4] [5] The most common genetic alterations in tumors with chromosomal instability are allelic losses, chromosomal amplifications, and translocations that affect mainly tumor-suppressor genes (APC, p53, and SMAD4) and some oncogenes (k-ras). 3 Cases with MSI display frameshift mutations and base-pair (bp) substitutions in microsatellites. 2, 4, [5] [6] [7] These errors normally are controlled and repaired by the DNA mismatch repair (MMR) genes, including hMLH1, hMSH2, hMSH6, hPMS2, and hMSH3.
Deficient MMR can arise sporadically or be inherited in an autosomal dominant manner in cases of the hereditary nonpolyposis colorectal cancer (HNPCC) syndrome. 1, 8, 9 In most HNPCC cases, the cause is an inherited germline mutation of 1 of the 3 main MMR genes (hMLH1, hMSH2, and hMSH6), leading to deficient MMR and, ultimately, cancer. 10, 11 However, about 15% of CRCs show MSI without evidence of germline abnormalities. In these cases, the cause is biallelic methylation of CpG islands in the promoter sequence of hMLH1, an epigenetic change that leads to a deficiency of MMR genes. [12] [13] [14] During the last few years, the detection of MSI has become increasingly more important. Not only does the detection of MSI permit the detection of familial colorectal cancer, but it also seems that the response of MSI cancers to chemotherapy is different from the response of cancers with chromosomal instability. As a consequence, the demand for MSI testing is increasing sharply. However, because systematic screening for MSI in CRC is not realistic, the development of a cost-effective strategy to detect HNPCC is more essential.
This study addresses the following questions: (1) Does morphologic assessment allow reliable prediction of MSI CRC? (2) Does immunohistochemical staining for hMLH1, hMSH2, and hMSH6 allow reliable prediction of MSI CRC? (3) Which proportion of MSI CRCs show methylation of the promoter of the hMLH1 gene? (4) Which combination of these approaches allows reliable and cost-effective identification of HNPCC?
Materials and Methods

Cases
Our cohort consisted of 148 consecutive CRC cases. Tumor specimens were obtained from surgical resection specimens performed at the Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, between February 2002 and June 2003. The present analysis was in accordance with the original informed consent signed by all patients.
Histopathologic Assessment
All tumor samples were reviewed by 2 pathologists (H.B. and L.T.) who were blinded to the molecular results. The following variables were assessed: tumor location, tumor TNM stage, tumor grade, 15 growth pattern, and lymphocytic host response. Tumors located before the splenic flexure were considered as right-sided and after as left-sided. The tumor growth pattern at the invasion front was examined at low power to determine whether the tumor grew with a pushing pattern or an infiltrative pattern. The invasion front of the tumor also was assessed for the presence of a Crohnlike inflammatory response. For this, at least 3 lymphoid aggregates per section were required. Tumor infiltrating lymphocytes (TILs) were identified on H&E-stained sections, and only lymphocytes infiltrating between tumor cells were counted. TILs were scored as absent or present when there were fewer or more than 4 lymphocytes per 100 epithelial cells. 16 Immunohistochemical Analysis for hMLH1, hMSH2, and hMSH6 Protein For each case, 1 paraffin-embedded block with tumor tissue and normal colonic tissue was selected for the detection of hMLH1, hMSH2, and hMSH6 protein. Tissue sections, 4 µm, were mounted on aminopropylmethoxysilane-coated glass slides, deparaffinized in xylene, taken through to absolute alcohol, and blocked for endogenous peroxidase with 0.3% hydrogen peroxide in methanol (45 minutes). They were subjected to microwave oven heating for 15 minutes in 10 mmol/L of citrate buffer, pH 6.0, and rinsed in Tris-buffered saline (TBS; 0.05 mol/L of tris(hydroxymethyl)aminomethane [Tris] and sodium chloride, 0.9%, pH 7.6).
Then, sections were incubated for 30 minutes at room temperature with the primary monoclonal antibody (hMLH1, Pharmingen, Basel, Switzerland; hMSH2, Pharmingen; and hMSH6, Becton Dickinson, Basel; diluted 1:50, 1:600, and 1:100, respectively, in TBS containing 5% nonfat dry milk). After rinsing with TBS, the slides were incubated with the EnVision+/mouse system (DAKO, Carpinteria, CA), directed against mouse monoclonal antibodies for 30 minutes at room temperature. Peroxidase activity was revealed with 5-5,diaminobenzidine as the chromogen, and the sections were counterstained in Mayer acid-free hematoxylin. For a negative control sample, the first-step monoclonal antibody was replaced by a hybridoma supernatant of similar isotype but without reactivity for the tissue examined. A positive reaction showed unequivocal nuclear staining of epithelial cells, including neoplastic cells ❚Image 1❚. Tumor cells without nuclear staining in the presence of a positive internal control were considered deficient for the antigen (Image 1).
MSI Analysis
For MSI analysis, microdissection was performed after identification of tumor tissue by a pathologist (H.B.). DNA was extracted from tumor tissue and from normal mucosa from 2 blocks to avoid contamination. 17 Extracted DNA was amplified by polymerase chain reaction (PCR), using the reference panel of microsatellite primers recommended for CRC by the National Cancer Institute, which includes the markers BAT25, BAT26, D5S346 (APC), D2S123 (hMSH2), and D17S250 (p53). 18 The presence of additional bands in the PCR products from tumor DNA that were not observed in DNA from corresponding normal tissue was scored as unstable at that particular locus. Tumor samples were classified as displaying high-frequency MSI (MSI-H) when instability was observed for 2 or more of the loci screened, low-frequency MSI (MSI-L) when fewer than 2 of the loci screened, or microsatellite stability (MSS) when stability was present at all the loci tested.
Methylation-Sensitive Single-Strand Conformation Analysis of the hMLH1 Promoter
We selected 15 tumor samples with MSI-H status and loss of immunostaining of hMLH1 for promoter methylation analysis. After deparaffinization and staining in 0.1% toluidine blue, histologically selected areas in tissue sections were microdissected manually. 17 Only the tumor cells were retained, and final histologic control before collection of the tumor cells confirmed that contamination with other cells was negligible. Extracted DNA was modified with sodium bisulfite as previously described. 19 A 178-bp fragment of the hMLH1 gene promoter was amplified by nested PCR using the following primers: forward, 5'-GATTTTTTAAGGTTAA-GAG-3', and reverse, 5'-ATAAAACCCTATACCTAATC-3', for the outer PCR; and forward, 5'-TTTTTAGGAGTGAAG-GAG-3', and reverse, 5'-AAACCCTATACCTAATCTATC-3', for the inner PCR amplification. The outer PCR amplification was performed with 2 µL of modified DNA in a total volume of 20 µL for 40 cycles. For the inner PCR, 20 cycles were performed. Amplification was confirmed by analysis on a 2% agarose gel. Single-strand conformation analysis was performed as previously described. 20 The percentage of methylated alleles was estimated semiquantitatively by comparing the intensity of the methylated and unmethylated bands ❚Image 2❚.
Statistical Analysis
Statistical analyses were carried out by using SPSS software, version 7.5 (SPSS, Chicago, IL). Quantitative data are expressed as mean ± SD. Group comparisons were made by using the χ 2 test for categorical variables and the t test for continuous variables. Appropriate binary variables were generated to identify each subgroup of interest. The parameters used in this analysis were as follows: age of the patients, sex, location of the tumor (proximal or distal colon), histologic grade, invasive vs pushing tumor edge, absence or presence of TILs, absence or presence of Crohn-like reaction, absence of expression of one of the DNA MMR genes (hMLH1, hMSH2, and hMSH6), and MSI status (MSI-H vs MSI-L or MSS). A logistic regression model was used in multivariate analysis to identify independent predictors of MSI, and variables in the final model included all variables statistically significant at a P value of less than .05 in the univariate analysis.
Results
Correlations between MSI status and clinicopathologic factors are summarized in ❚Table 1❚. In our series of 148 CRC cases, the mean age of the patients was 76. Table 2) . One tumor showed loss of staining for hMSH6.
The mean age of patients with MSI-H tumors was 76.5 years; the youngest patient was 44 years old. All tumors with a loss of hMSH2 occurred in men. The incidence of tumors in the proximal colon was higher in MSI-H than in MSI-L/MSS tumors (48% vs 30%; P < .0001).
MSI-H tumors were more often of the mucinous type than MSI-L/MSS tumors (48% vs 12%; P < .0001). Of the negative hMSH2 tumors, 75% were of the mucinous type, whereas only 47% of the negative hMLH1 tumors were mucinous. MSI-H tumors more often had a peritumoral and/or TIL than MSI-L/MSS tumors; however, only a TIL reaction correlated significantly with MSI-H status (P = .002). Of 21 MSI-H tumors, 3 were located in the left colon, but all were of the mucinous type and 2 of them had TILs. All 10 MSI-H carcinomas, not otherwise specified, were located in the right colon, and 6 of them had TILs. There was no difference in age, pT, lymph node involvement, tumor growth, or Crohn-like lymphoid reaction between patients with MSI-H and MSI-L/MSS tumors. In multivariate analysis, only the location in the right colon and a marked TIL reaction correlated highly with MSI-H.
Low-Frequency MSI
Of the 148 tumors, 3 were MSI-L, and they all showed instability of 1 marker other than BAT25 and BAT26 ❚Table 3❚. Immunohistochemical MMR gene expression was normal in these cases. The tumors were located in the left colon, and none of them had morphologic characteristics correlated with MSI-H. 
MSS Cases
There were 124 MSS cases. The mean age of patients was 69 years, and 9 patients were younger than 50 years. The tumors were located more often in the left (87 [70.2%]) than in the right (37 [30.0%]) colon (Table 1) . In 68 tumors (54.8%), a peritumoral Crohn-like lymphocytic reaction was found, whereas in only 22 tumors (17.7%) were marked TILs found. There were 104 adenocarcinomas, not otherwise specified; 15 mucinous carcinomas; 4 undifferentiated carcinomas; and 1 signet-ring cell carcinoma. All MSS tumors had intact labeling for all MMR proteins.
Methylation
Of the 15 MSI-H tumors with loss of immunohistochemical staining for hMLH1, 12 (80%) showed methylation of the hMLH1 promoter and 3 (20%) were not methylated for hMLH1, indicating the possibility of germline mutation. These 3 cases had at least 3 unstable markers, and 1 of the unmethylated tumors also had loss of immunohistochemical staining for hMSH6. There was no morphologic difference between tumors with methylation and those without methylation of the hMLH1 promoter. However, the patients with MSI-H cancer without methylation of the hMLH1 promoter gene were younger (median age, 58 years) than patients with MSI-H cancer with methylation of hMLH1 (median age, 81 years).
Correlations of MSI-H, Immunohistochemical Analysis, and Methylation
Immunohistochemical staining for hMLH1, hMSH2, and hMSH6 was a highly sensitive (95%) and specific (100%) predictor for MSI. hMLH1 promoter methylation invariably correlated with instability of BAT25 and BAT26 markers.
Discussion
MSI results from a defect of the MMR system inducing an accumulation of somatic alterations in the length of simple repeated sequences called microsatellites. 5, 7, [11] [12] [13] 18, 21, 22 MSI is a phenotypic indicator of defective DNA MMR and is present in most cases of HNPCC and in 10% to 15% of various sporadic cancers, such as colon, endometrial, and stomach. 2, 4, 5, 22, 23 In HNPCC, germline mutations have been identified in 5 MMR genes, hMSH2, hMLH1, hPMS1, hPMS2, and hHML6, but the majority of the mutations occur in hMLH1 and hMSH2. HNPCC is defined clinically by the Amsterdam I and II criteria. 18, 24, 25 Because clinical criteria are not sensitive enough for HNPCC, MSI could be used as a surrogate marker for HNPCC. Testing for MSI would, however, serve other purposes than detection of HNPCC. MSI testing could represent a prognostic indicator because many studies, including a recent meta-analysis, showed that a better prognosis is associated with MSI-H tumors than MSS colonic cancers. [26] [27] [28] [29] [30] [31] Moreover, it has been shown that the response of MSI CRCs is different from that of MSS CRC to adjuvant chemotherapy. 26, 29, 30, 32, 33 The current "gold standard" for assessing tumor DNA mismatch pair competency is molecular MSI testing. For this MSI testing, the National Cancer Institute (NCI) has recommended a panel of 5 markers, known as Bethesda (or NCIpanel) markers, which includes 2 mononucleotides, BAT25 and BAT26, and 3 dinucleotide repeats, D2S123, D5S346, and D17S250. 18 Two distinct microsatellite tumor phenotypes have been described: MSI-H (MSI at >30% of microsatellites examined) and MSI-L or microsatellite stable (MSS) (MSI at <30% microsatellites examined). The MSI-H phenotype is found in about 10% to 15% of sporadic colon tumors and in the majority of tumors from patients with the HNPCC. 18 The MSI-L phenotype is more rare, and there is debate whether it is a distinct phenotype or merely an artifact of highly sensitive techniques. 28, 34 In our study, the incidence of MSI-H tumors was 14.2%, which is within the range reported in previous studies (12%-20%). 4, 5, 14 The incidence of MSI-L tumors was 2.0%, and these tumors did not fulfill the clinicopathologic criteria for MSI.
Recently, some studies showed that BAT25 and BAT26 are the most common altered microsatellites and were the most sensitive and specific markers, able to identify more than 95% of MSI cases. 25, 35 This is in agreement with our results; we found that all MSI-H cases but 1 had BAT25 and BAT26 instability. Among the 3 cases with MSI-L cancers, none had BAT-25 or BAT-26 instability. Our results support the fact that using one of the mononucleotides, BAT-25 or BAT-26, is sensitive enough (95%) for MSI testing. However, even if the detection of MMR deficiency is limited to 1 or 2 markers, it remains a labor-intensive and expensive test.
The detection of MSI could be done by immunohistochemical analysis by using antibodies directed against DNA MMR enzymes. Lack of expression of one of the MMR proteins has essentially perfect specificity for MSI-H status, and immunohistochemical analysis could be used as a surrogate marker for MSI. [36] [37] [38] [39] The correspondence between MSI analysis and immunohistochemical analysis varies from one series to another. However, the discrepancy is generally less than 10%. 35, [39] [40] [41] [42] [43] To limit this discrepancy, immunohistochemical analysis of MMR proteins must be performed in standardized conditions and interpreted by experienced pathologists. We found in our series that absence of expression of hMLH1, hMSH2, and hMSH6 had a sensitivity of 95% and a specificity of 100% for predicting a tumor with the MSI-H phenotype. Only 1 case was found to be MSI-H but with normal expression of MMR genes.
If test costs are set according to actual workload, immunohistochemical analysis will be much less expensive than MSI testing and can be performed more rapidly. On the basis of our experience, using workload recordings, we would agree with the cost estimation by Debniak et al, 42 who estimated that immunohistochemical analysis costs only 25% of what MSI testing costs. Similar to the findings in a recent study by Hampel et al, 39 we found that the effectiveness of screening with immunohistochemical analysis of the MMR proteins would be similar to that of genotyping for MSI. In addition, another substantial advantage of tumor immunohistochemical analysis over MSI testing is that immunohistochemical analysis provides relevant information about underlying germline mutations and will guide clinicians to the correct gene for genetic testing in individuals and families in which the issue of HNPCC is being studied.
Shia et al 44 reported that immunohistochemical sensitivity was lower in HNPCC cases than in sporadic cases. The discrepancies in the literature data on the sensitivity of immunohistochemical analysis for MSI might be due to the proportions of hereditary vs sporadic CRC cases. One must be aware of the possible underdetection of MSI by immunohistochemical analysis, implying that when there is a strong evidence of familial CRC and the immunohistochemical results are noncontributory, this analysis must be complemented by PCR.
Loss of hMSH2 expression frequently is associated with germline mutations, whereas loss of hMLH1 expression frequently is associated with gene methylation. 40 The implications of hMSH6 in MSI tumors are not clear because few series have analyzed predictive value in MSI-H tumors. In our series, 4 MSI-H tumors had loss of expression of hMSH2 and could be correlated with HNPCC syndrome, and 15 MSI-H tumors were missing hMLH1 expression. One tumor had loss of hMSH6 protein associated with alteration of BAT25 and BAT26 mononucleotide repeats, and this patient might have a germline mutation in the hMSH6 gene. 38 Hypermethylation of the hMLH1 promoter may be the principal mechanism of gene inactivation in sporadic CRC characterized by widespread MSI. 12, 14 We found that 80% of tumors with loss of immunostaining for hMLH1 showed a methylation of the hMLH1 promoter. Of the tumors with hMLH1 silencing, 20% showed no methylation, and, consequently, one can speculate that these tumors could have a mutation of hMLH1.
One of the concerns in our daily practice is to know whether MSI testing is indicated in all CRCs or only in selected cases. Distinct clinicopathologic features of colorectal tumors arising from chromosomal instability and MSI have been identified and, thus, could be used as criteria for selection for MSI testing. 10, 15, 42 One of our questions is the reliability of the clinicopathologic features for predicting MSI CRC in our series of cases.
One of the Amsterdam criteria is younger age at the time of HNPCC diagnosis. In our series, the mean age of patients with MSI-H tumors was 76 years and was not correlated with microsatellite status. This fact has clinical importance because advanced age at diagnosis of CRC does not exclude completely the possibility of HNPCC and could not be used as a discriminant criterion for MSI testing. However, we observed that patients with unmethylated hMLH1-1 tumors were younger than those with methylated tumors.
In agreement with the findings of most previous studies, 1,5,45 we found that MSI-H tumors tended to be located proximally in the colon and were more often mucinous carcinoma compared with MSI-L/MSS tumors. It is of note that in our series, hMSH2 carcinomas more frequently were mucinous than hMLH1 tumors (75% vs 47%). Because colon carcinomas with hMSH2 silencing belong to the HNPCC syndrome, the mucinous type becomes an important discriminant criterion. MSI-H tumors may have an enhanced immunologic response. The presence of a prominent Crohn-like response and a marked number of TILs were found to be markers of MSI-H tumors. 8, 9, 16 In our study, we found that the TIL reaction correlated highly with MSI-H CRC but not the Crohn-like reaction. Studies that have used T-cell markers to identify TILs have, not surprisingly, found a higher absolute number of TILs in MSI-H tumors than studies that relied on H&E identification. We performed this exercise (data not shown), but we did not find a significant difference between H&E and immunoperoxidase detection of TILs. Using immunoperoxidase techniques to identify TILs adds additional expense, which we think is unnecessary to screen for MSI-H tumors.
Our study has confirmed the reliability of some previously recognized morphologic predictors of MSI-H tumors that can be used as a basis for MSI testing. We found an excellent correlation between MSI status and MMR protein expression, supporting immunohistochemical analysis as a rapid, cost-effective, and reliable method for detecting CRCs defective in MMR genes. However, in cases with normal expression of MMR genes but that have the Amsterdam criteria for HNPCC syndrome, further molecular analysis should be performed. For this, examination of the mononucleotide-repeat markers BAT25 or BAT26 alone would have been sufficient for detecting MMR-defective tumors. The search for hMLH1 promoter methylation can be a useful complement to detect HNPCC syndrome.
According to our results we propose an algorithm that seems to be the most cost-effective and timesaving procedure for the detection of HNPCC cases ❚Figure 1❚. First, selection of MSI searching would be based on CRC morphologic assessment, and immunohistochemical analysis might represent the first step in MSI detection. Second, in cases of abnormal expression of the hMLH1 protein, the search for hMLH1 methylation should be required and represent the second step. Third, in nonmethylated hMLH1 cases and in
